Replies to post #186704 on Biotech Values

[DewDiligence]

ABT +3% on solid 4Q14 results/2015 outlook—despite currency headwinds:

http://www.wsj.com/articles/abbott-laboratories-profit-grows-54-1422538479

Guidance for 2015 non-GAAP EPS is $2.10-2.20 (excluding the branded-generics business being sold to MYL) vs $2.28 in 2014 (including the business being sold to MYL).

At current exchange rates, the stronger US dollar compared to 2014 is expected to shave ABT’s 2015 sales by 6% and EPS by 10%. These currency effects are less severe than for many US-based multinationals because ABT makes a lot of its products locally, especially in India and China.

[DewDiligence]

98% of MYL shareholders endorse “spinversion” into a new Netherlands-based company derived from part of ABT:

#msg-110385639